Malignant skin melanoma detection using image augmentation by oversampling in nonlinear lower-dimensional embedding manifold

The continuous rise in skin cancer cases, especially in malignant melanoma, has resulted in a high mortality rate of the affected patients due to late detection. Some challenges affecting the success of skin cancer detection include small datasets or data scarcity problem, noisy data, imbalanced data, inconsistency in image sizes and resolutions, unavailability of data, reliability of labeled data (ground truth), and imbalance of skin cancer datasets. This study presents a novel data augmentation technique based on covariant Synthetic Minority Oversampling Technique (SMOTE) to address the data scarcity and class imbalance problem. We propose an improved data augmentation model for effective detection of melanoma skin cancer. Our method is based on data oversampling in a nonlinear lower-dimensional embedding manifold for creating synthetic melanoma images. The proposed data augmentation technique is used to generate a new skin melanoma dataset using dermoscopic images from the publicly available P H2 dataset. The augmented images were used to train the SqueezeNet deep learning model. The experimental results in binary classification scenario show a significant improvement in detection of melanoma with respect to accuracy (92.18%), sensitivity (80.77%), specificity (95.1%), and F1-score (80.84%). We also improved the multiclass classification results in melanoma detection to 89.2% (sensitivity), 96.2% (specificity) for atypical nevus detection, 65.4% (sensitivity), 72.2% (specificity), and for common nevus detection 66% (sensitivity), 77.2% (specificity). The proposed classification framework outperforms some of the state-of-the-art methods in detecting skin melanoma.publishedVersio

Asymptomatic malaria infections and Pfmdr1 mutations in an endemic area of Nigeria

Background: Malaria eradication globally is yet to be achieved and transmission is sustained in many endemic countries. Plasmodium falciparum continues to develop resistance to currently available anti-malarial drugs, posing great problems for malaria elimination. This study evaluates the frequencies of asymptomatic infection and multidrug resistance- 1 (mdr-1) gene mutations in parasite isolates, which form the basis for understanding persistently high incidence in South West, Nigeria. Methods: A total of 535 individuals aged from 6 months were screened during the epidemiological survey evaluating asymptomatic transmission. Parasite prevalence was determined by histidine-rich protein II rapid detection kit (RDT) in healthy individuals. Plasmodium falciparum mdr-1 gene mutations were detected by polymerase chain reaction (PCR) followed by restriction enzyme digest and electrophoresis to determine polymorphism in parasite isolates. Sequencing was done to confirm polymorphism. Proportions were compared using Chi-square test at p value < 0.05. Results: Malaria parasites were detected by RDT in 204 (38.1%) individuals. Asymptomatic infection was detected in 117 (57.3%) and symptomatic malaria confirmed in 87 individuals (42.6%). Overall, individuals with detectable malaria by RDT was significantly higher in individuals with symptoms, 87 of 197 (44.2%), than asymptomatic persons; 117 of 338 (34.6%), p = 0.02. In a sub-set of 75 isolates, 18(24%) and 14 (18.6%) individuals had Pfmdr1 86Y and 1246Y mutations. Conclusions: There is still high malaria transmission rate in Nigeria with higher incidence of asymptomatic infections. These parasites harbour mutations on Pfmdr1 which contribute to artemisinin partner drug resistance; surveillance strategies to reduce the spread of drug resistance in endemic areas are needed to eliminate the reservoir of malaria parasites that can mitigate the eradication of malaria in Nigeri

Nanochitosan derived from marine bacteria

Nanochitosans are polysaccharides produced by the alkalescent deacetylation of chitin and comprise a series of 2‐deoxy‐2 (acetylamino) glucose linked by ß‐(1‐4) glycosidic linkages. These are naturally formed from the deacetylation of shellfish shells and the exoskeleton of aquatic arthropods and crustaceans. Reports of chitosan production from unicellular marine bacteria inhabiting the sea, and possessing distinct animal‐ and plant‐like characteristics abound. This capacity to synthesize chitosan from chitin arises from response to stress under extreme environmental conditions, as a means of survival. Consequently, the microencapsulation of these nanocarriers results in new and improved chitosan nanoparticles, nanochitosan. This nontoxic bioactive material which can serve as an antibacterial agent, gene delivery vector as well as carrier for protein and drug release as compared with chitosan, is limited by its nonspecific molecular weight and higher composition of deacetylated chitin. This chapter highlights the biology and diversity of nanochitosan‐producing marine bacteria, including the factors influencing their activities, survival, and distribution. More so, the applications of marine bacterial nanochitosans in transfection and gene delivery; wound healing and drug delivery; feed supplement development and antimicrobial activity are discussed

Utilization of nanochitosan in the sterilization of ponds and water treatment for aquaculture

Water pollution constitutes the leading cause of infant mortality, neonatal deformities, and shrinkage of man’s average life expectancy. Pollutants come from point and nonpoint sources; and water pollution arises from the discharge of wastewater containing undesirable impurities used for domestic, agricultural, and industrial purposes. More so, high nutrient and wastewater runoffs from fish production systems contribute to the fouling and eutrophication of recipient water bodies. Hence, aquaculture which is inextricably linked to the natural environment is challenged by the dearth of appropriate water quantity and quality, militating against fish, and fishery production. Nanochitosans as polysaccharides produced by the alkalescent deacetylation of chitin, comprise a series of 2-deoxy-2 (acetylamino) glucose linked by ß-(1-4) glycosidic linkages. They are naturally formed from the deacetylation of shellfish shells and exoskeletons of aquatic arthropods and crustaceans. The unique attributes of chitin confer a wide range of biotechnological applications on the polymer, observed in flocculation as a wastewater treatment and purification route initiated by chitosan. This chapter highlights nanochitosan properties of aquaculture relevance; and elucidates the purification potentials of nanochitosan, compared to inorganic coagulants and organic polymeric flocculants. Effects of chitosan on contaminants and microorganisms, as well as applications in fish pathogens detection, fish disease diagnosis, and control are discussed

Chapter 21 - Utilization of nanochitosan in the sterilization of ponds and water treatment for aquaculture

Water pollution constitutes the leading cause of infant mortality, neonatal deformities, and shrinkage of man’s average life expectancy. Pollutants come from point and nonpoint sources; and water pollution arises from the discharge of wastewater containing undesirable impurities used for domestic, agricultural, and industrial purposes. More so, high nutrient and wastewater runoffs from fish production systems contribute to the fouling and eutrophication of recipient water bodies. Hence, aquaculture which is inextricably linked to the natural environment is challenged by the dearth of appropriate water quantity and quality, militating against fish, and fishery production. Nanochitosans as polysaccharides produced by the alkalescent deacetylation of chitin, comprise a series of 2-deoxy-2 (acetylamino) glucose linked by ß-(1-4) glycosidic linkages. They are naturally formed from the deacetylation of shellfish shells and exoskeletons of aquatic arthropods and crustaceans. The unique attributes of chitin confer a wide range of biotechnological applications on the polymer, observed in flocculation as a wastewater treatment and purification route initiated by chitosan. This chapter highlights nanochitosan properties of aquaculture relevance; and elucidates the purification potentials of nanochitosan, compared to inorganic coagulants and organic polymeric flocculants. Effects of chitosan on contaminants and microorganisms, as well as applications in fish pathogens detection, fish disease diagnosis, and control are discussed

Utilization of nanochitosan for enzyme immobilization of aquatic and animal-based food packages

Studies have identified the properties of enzymes, functionalized molecules, and compounds in food industry applications as edible coatings and encapsulations, that assure prolonged food quality and standards. These molecules present benefits of longer shelf-life by delayed deterioration and inhibition of the proliferation of spoilage and mycotoxigenic microorganisms. However, challenges of reduced nutrient levels, miniaturized size, and low chemical stability remain concerning. Chitosan polymers naturally formed from the deacetylation of shellfish shells and exoskeletons of aquatic arthropods and crustaceans offer improved benefits when functionalized into nanoparticles as nanochitosans. These polysaccharides produced by the alkalescent deacetylation of chitin, comprise a series of 2-deoxy-2 (acetylamino) glucose linked by ß-(1-4) glycosidic linkages. This chapter considers the health impacts and

Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18 : a modelling study

Background: High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units across sub-Saharan Africa. Methods: In this modelling study, we developed a framework that used the geographically specific HIV prevalence data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to estimate HIV prevalence at the second administrative level in 44 countries in sub-Saharan Africa for 2000–18 and sought data on the number of individuals on antiretroviral therapy (ART) by second-level administrative unit. We then modified the Estimation and Projection Package (EPP) to use these HIV prevalence and treatment estimates to estimate HIV incidence and mortality by second-level administrative unit. Findings: The estimates suggest substantial variation in HIV incidence and mortality rates both between and within countries in sub-Saharan Africa, with 15 countries having a ten-times or greater difference in estimated HIV incidence between the second-level administrative units with the lowest and highest estimated incidence levels. Across all 44 countries in 2018, HIV incidence ranged from 2 ·8 (95% uncertainty interval 2·1–3·8) in Mauritania to 1585·9 (1369·4–1824·8) cases per 100 000 people in Lesotho and HIV mortality ranged from 0·8 (0·7–0·9) in Mauritania to 676· 5 (513· 6–888·0) deaths per 100 000 people in Lesotho. Variation in both incidence and mortality was substantially greater at the subnational level than at the national level and the highest estimated rates were accordingly higher. Among second-level administrative units, Guijá District, Gaza Province, Mozambique, had the highest estimated HIV incidence (4661·7 [2544·8–8120·3]) cases per 100000 people in 2018 and Inhassunge District, Zambezia Province, Mozambique, had the highest estimated HIV mortality rate (1163·0 [679·0–1866·8]) deaths per 100 000 people. Further, the rate of reduction in HIV incidence and mortality from 2000 to 2018, as well as the ratio of new infections to the number of people living with HIV was highly variable. Although most second-level administrative units had declines in the number of new cases (3316 [81· 1%] of 4087 units) and number of deaths (3325 [81·4%]), nearly all appeared well short of the targeted 75% reduction in new cases and deaths between 2010 and 2020. Interpretation: Our estimates suggest that most second-level administrative units in sub-Saharan Africa are falling short of the targeted 75% reduction in new cases and deaths by 2020, which is further compounded by substantial within-country variability. These estimates will help decision makers and programme implementers expand access to ART and better target health resources to higher burden subnational areas

Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]) associated with 19 risk factors, for 204 countries and territories from 1990 to 2019. These estimates were provided for ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, and all strokes combined, and stratified by sex, age group, and World Bank country income level. Findings In 2019, there were 12·2 million (95% UI 11·0–13·6) incident cases of stroke, 101 million (93·2–111) prevalent cases of stroke, 143 million (133–153) DALYs due to stroke, and 6·55 million (6·00–7·02) deaths from stroke. Globally, stroke remained the second-leading cause of death (11·6% [10·8–12·2] of total deaths) and the third-leading cause of death and disability combined (5·7% [5·1–6·2] of total DALYs) in 2019. From 1990 to 2019, the absolute number of incident strokes increased by 70·0% (67·0–73·0), prevalent strokes increased by 85·0% (83·0–88·0), deaths from stroke increased by 43·0% (31·0–55·0), and DALYs due to stroke increased by 32·0% (22·0–42·0). During the same period, age-standardised rates of stroke incidence decreased by 17·0% (15·0–18·0), mortality decreased by 36·0% (31·0–42·0), prevalence decreased by 6·0% (5·0–7·0), and DALYs decreased by 36·0% (31·0–42·0). However, among people younger than 70 years, prevalence rates increased by 22·0% (21·0–24·0) and incidence rates increased by 15·0% (12·0–18·0). In 2019, the age-standardised stroke-related mortality rate was 3·6 (3·5–3·8) times higher in the World Bank low-income group than in the World Bank high-income group, and the age-standardised stroke-related DALY rate was 3·7 (3·5–3·9) times higher in the low-income group than the high-income group. Ischaemic stroke constituted 62·4% of all incident strokes in 2019 (7·63 million [6·57–8·96]), while intracerebral haemorrhage constituted 27·9% (3·41 million [2·97–3·91]) and subarachnoid haemorrhage constituted 9·7% (1·18 million [1·01–1·39]). In 2019, the five leading risk factors for stroke were high systolic blood pressure (contributing to 79·6 million [67·7–90·8] DALYs or 55·5% [48·2–62·0] of total stroke DALYs), high body-mass index (34·9 million [22·3–48·6] DALYs or 24·3% [15·7–33·2]), high fasting plasma glucose (28·9 million [19·8–41·5] DALYs or 20·2% [13·8–29·1]), ambient particulate matter pollution (28·7 million [23·4–33·4] DALYs or 20·1% [16·6–23·0]), and smoking (25·3 million [22·6–28·2] DALYs or 17·6% [16·4–19·0]). Interpretation The annual number of strokes and deaths due to stroke increased substantially from 1990 to 2019, despite substantial reductions in age-standardised rates, particularly among people older than 70 years. The highest age-standardised stroke-related mortality and DALY rates were in the World Bank low-income group. The fastest-growing risk factor for stroke between 1990 and 2019 was high body-mass index. Without urgent implementation of effective primary prevention strategies, the stroke burden will probably continue to grow across the world, particularly in low-income countries.publishedVersio

Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

Background: Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with standardised and replicable methods. Methods: We estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods. We based the estimates on the demographic balancing equation, with inputs of fertility, mortality, population, and migration data. Fertility data came from 7817 location-years of vital registration data, 429 surveys reporting complete birth histories, and 977 surveys and censuses reporting summary birth histories. We estimated age-specific fertility rates (ASFRs; the annual number of livebirths to women of a specified age group per 1000 women in that age group) by use of spatiotemporal Gaussian process regression and used the ASFRs to estimate total fertility rates (TFRs; the average number of children a woman would bear if she survived through the end of the reproductive age span [age 10–54 years] and experienced at each age a particular set of ASFRs observed in the year of interest). Because of sparse data, fertility at ages 10–14 years and 50–54 years was estimated from data on fertility in women aged 15–19 years and 45–49 years, through use of linear regression. Age-specific mortality data came from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 estimates. Data on population came from 1257 censuses and 761 population registry location-years and were adjusted for underenumeration and age misreporting with standard demographic methods. Migration was estimated with the GBD Bayesian demographic balancing model, after incorporating information about refugee migration into the model prior. Final population estimates used the cohort-component method of population projection, with inputs of fertility, mortality, and migration data. Population uncertainty was estimated by use of out-of-sample predictive validity testing. With these data, we estimated the trends in population by age and sex and in fertility by age between 1950 and 2017 in 195 countries and territories. Findings: From 1950 to 2017, TFRs decreased by 49\ub74% (95% uncertainty interval [UI] 46\ub74–52\ub70). The TFR decreased from 4\ub77 livebirths (4\ub75–4\ub79) to 2\ub74 livebirths (2\ub72–2\ub75), and the ASFR of mothers aged 10–19 years decreased from 37 livebirths (34–40) to 22 livebirths (19–24) per 1000 women. Despite reductions in the TFR, the global population has been increasing by an average of 83\ub78 million people per year since 1985. The global population increased by 197\ub72% (193\ub73–200\ub78) since 1950, from 2\ub76 billion (2\ub75–2\ub76) to 7\ub76 billion (7\ub74–7\ub79) people in 2017; much of this increase was in the proportion of the global population in south Asia and sub-Saharan Africa. The global annual rate of population growth increased between 1950 and 1964, when it peaked at 2\ub70%; this rate then remained nearly constant until 1970 and then decreased to 1\ub71% in 2017. Population growth rates in the southeast Asia, east Asia, and Oceania GBD super-region decreased from 2\ub75% in 1963 to 0\ub77% in 2017, whereas in sub-Saharan Africa, population growth rates were almost at the highest reported levels ever in 2017, when they were at 2\ub77%. The global average age increased from 26\ub76 years in 1950 to 32\ub71 years in 2017, and the proportion of the population that is of working age (age 15–64 years) increased from 59\ub79% to 65\ub73%. At the national level, the TFR decreased in all countries and territories between 1950 and 2017; in 2017, TFRs ranged from a low of 1\ub70 livebirths (95% UI 0\ub79–1\ub72) in Cyprus to a high of 7\ub71 livebirths (6\ub78–7\ub74) in Niger. The TFR under age 25 years (TFU25; number of livebirths expected by age 25 years for a hypothetical woman who survived the age group and was exposed to current ASFRs) in 2017 ranged from 0\ub708 livebirths (0\ub707–0\ub709) in South Korea to 2\ub74 livebirths (2\ub72–2\ub76) in Niger, and the TFR over age 30 years (TFO30; number of livebirths expected for a hypothetical woman ageing from 30 to 54 years who survived the age group and was exposed to current ASFRs) ranged from a low of 0\ub73 livebirths (0\ub73–0\ub74) in Puerto Rico to a high of 3\ub71 livebirths (3\ub70–3\ub72) in Niger. TFO30 was higher than TFU25 in 145 countries and territories in 2017. 33 countries had a negative population growth rate from 2010 to 2017, most of which were located in central, eastern, and western Europe, whereas population growth rates of more than 2\ub70% were seen in 33 of 46 countries in sub-Saharan Africa. In 2017, less than 65% of the national population was of working age in 12 of 34 high-income countries, and less than 50% of the national population was of working age in Mali, Chad, and Niger. Interpretation: Population trends create demographic dividends and headwinds (ie, economic benefits and detriments) that affect national economies and determine national planning needs. Although TFRs are decreasing, the global population continues to grow as mortality declines, with diverse patterns at the national level and across age groups. To our knowledge, this is the first study to provide transparent and replicable estimates of population and fertility, which can be used to inform decision making and to monitor progress. Funding: Bill &amp; Melinda Gates Foundation